Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

efined by RECIST criteria), decreases in CA 19-9 (a tumor marker in some patients with pancreatic cancer), and the overall duration of response in those patients achieving a response. In addition, amelioration of pain and reduction in analgesic use will be quantified as another measure of clinical benefit.

Patients will remain on study until tumor progression or death, unacceptable toxicity, withdrawal of consent or discontinuation based upon investigator discretion. Patients will be followed for survival for up to one year after enrollment in the study.

"We are structuring a diversified Phase 2 program for TPI 287 that will allow us to effectively evaluate this unique taxane as a treatment option for patients who have failed other therapeutic regimens," commented Dr. Sandra Silberman, chief medical officer of Tapestry Pharmaceuticals. "Our primary goal in this study is to rigorously explore the activity of TPI 287 in patients with advanced pancreatic cancer who have failed first line therapy. We are also interested in building more experience with this compound in the clinic, defining its safety and side-effect profile and tracking its impact on the quality of patients' lives, particularly as it relates to pain and pain management."

Clinical Program for TPI 287

In addition to the dosing of the first patient in this Phase 2 advanced pancreatic cancer trial and the on-going Phase 2 clinical trial in patients with advanced, hormone refractory prostate cancer, the Company may begin a third Phase 2 clinical trial in patients with glioblastoma multiforme, a primary cancer of the central nervous system. In all of these Phase 2 studies, TPI 287 will be administered as an intravenous dosage form.

In parallel to these Phase 2 studies, the company plans to initiate a Phase 1b study evaluating the oral bioavailability of TPI 287. In 2008, assuming feasibility of oral dosing from this study, the company may initiate a Phase 1b/2 study of the combin
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 25, 2015 Research and Markets( http://www.researchandmarkets.com/research/v7nm4b/2015_strategies ... "2015 Strategies in the Global Coagulation Testing Market" ... comprehensive seven-country report contains 650 pages, 150 tables, ... potential market entrants identify and evaluate business opportunities ... the next five years. The report ...
(Date:5/27/2015)... RICHMOND, Va. , May 27, 2015  Virginia ... its practice to resolve vaginal health issues often caused ... virtually painless and requires no anesthesia, received FDA clearance ... is one of the first practices in ... 2 laser specifically designed to help postmenopausal women ...
(Date:5/27/2015)... EATONTOWN, N.J. , May 27, 2015 /PRNewswire/ ... Ideomotion, LLC, utilizes a Motion Systems Corporation ball ... and freedom. Motion Systems manufactures the industry,s largest ... fit to a wide array of industries, including ... to help people who are wheelchair-bound as well ...
Breaking Medicine Technology:Global Coagulation Testing Market Strategies 2015 2Global Coagulation Testing Market Strategies 2015 3Virginia Women's Center Welcomes The Newest Breakthrough In Women's Health Treatment 2Virginia Women's Center Welcomes The Newest Breakthrough In Women's Health Treatment 3Innovative Technology Liberates the Wheelchair-Bound 2
... - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ), ... in an open label, dose-escalation, Phase 1 clinical trial ... patients with bladder cancer. This trial is separate from ... in patients with various solid tumors. OGX-427 is a ...
... MINNEAPOLIS, Aug. 11 ProUroCare Medical, Inc. (OTC Bulletin Board: ... three centers in its FDA clinical study of the ProUroScan imaging ... ProUroCare began the current study with the objective of ... than 40 patients enrolled overall. Since beginning, five clinical sites ...
Cached Medicine Technology:OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 2OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 3OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 4ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 2ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 3
(Date:5/27/2015)... Rolling Meadows, IL (PRWEB) May 27, 2015 ... the release of its SonarMD Platform, a ... engaging, monitoring and managing patients with chronic ... Lawrence Kosinski, MD, MBA, the application allows ... between visits through the ongoing use of ...
(Date:5/27/2015)... SmarterSkin, http://www.smarterskindermatology.com , is taking skin ... that makes it easier for patients to find skin care ... Dr. Sejal Shah is a cosmetic dermatologist based in New ... the test. This revolutionary DNA test uses 16 genetic markers ... , 1. Firmness and elasticity , 2. Glycation ...
(Date:5/27/2015)... CRN International, the radio marketing and promotions ... Financial Officer. , Prinner most recently was Principal of ... financial/operational executive positions at telecom and technology services companies ... and SNET. His accounting and consulting career began ... will be able to tap into his experience of ...
(Date:5/27/2015)... May 27, 2015 Representatives from Classified ... year’s conference of the American Immigration Lawyers Association (AILA). ... National Resort. MCA’s booth is #404. , The annual ... Immigration Law.” MCAads.com, a regular AILA conference attendee, describes ... they welcome current clients to their booth and make ...
(Date:5/27/2015)... 27, 2015 National Healthcare ... award winning web development and interactive marketing ... the launch of its newly redesigned, custom ... National Healthcare Providers, is a physician owned ... the areas of Radiology, Anesthesiology, Emergency and ...
Breaking Medicine News(10 mins):Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2Health News:CRN International Names New Chief Financial Officer 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 3Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3
... reason not to eat pate de foie gras is discussed ... States, Washington DC in a forthcoming issue of the ... , Harmful proteins fragments known as amyloid fibrils associated with ... cells in Type II diabetes can be present in the ...
... Scientists at the University of Liverpool will launch a ... such as HIV and tuberculosis. , The Centre, which ... the Health Protection Agency, is one of 12 in ... for Health Research (NIHR) as part of the Government,s ...
... CHARLOTTE, N.C., Feb. 10 USHIFU, a worldwide ... invasive high intensity focused,ultrasound technologies, is pleased to ... consulting position of Chief Medical Officer. Dr.,Schoenberg is ... Urologic,Oncology who has authored more than 100 peer-reviewed ...
... Feb. 10 Erdman, A Cogdell Spencer,Company is ... Erdman,Place, has earned the U.S. Environmental Protection Agency,s ... energy efficiency,and environmental protection. America,s commercial buildings and ... of similar facilities for energy,efficiency may qualify for ...
... SAN DIEGO, Feb. 10 NuVasive, Inc. (Nasdaq: ... developing products for minimally disruptive surgical treatments for the ... & Chief Financial Officer, is scheduled to present at ... The Ritz-Carlton Hotel in Laguna Niguel, California on Tuesday, ...
... one-of-a-kind claims processing, business intelligence, and portal ... in the 21st-century healthcare marketplaceBURLINGTON, Mass., Feb. ... modern, enterprise-class software platform for healthcare payors, ... selected the HealthRules product suite as their ...
Cached Medicine News:Health News:Give the foie gras a miss 2Health News:Biomedical research center opens in Liverpool 2Health News:USHIFU Appoints Mark Schoenberg, M.D. Chief Medical Officer 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 3Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 4Health News:NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference 2Health News:NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference 3Health News:Mississippi Administrative Services Chooses the HealthRules(R) Product Suite from HealthEdge(R) to Address Next-Generation Business Needs 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: